Efficient, Mutation-Free, Large-Payload Gene Therapy of iPS

Posted by Michael Rae on May 23, 2011 | Chief Science Officer's Team

Efficient, safe methods of gene therapy will be essential enabling technologies for the repair or obviation of several of the cellular and molecular lesions driving age-related disease and dysfunction. A recent paper from the Scripps Institute demonstrates a major step in this direction with the successful use of helper-dependent adenoviral vectors to rescue cells defective in lamin A, without detectable mutational side-effects.

Rescue of Oxidative Phosphorylation with "Allotopic" mRNA

Posted by Michael Rae on April 09, 2011 | Chief Science Officer's Team

At the third SENS conference, Dr. Samit Adhya of the Indian Institute of Chemical Biology presented a proof-of-principle for the use of an RNA import complex adapted from the parasite Leishmania to import arbitrary antisense RNA strands into mammalian mitochondria, reducing levels of a target protein by RNA interference. In a new study, Adhya's group reports the successful use of the same technique to deliver mRNA sequences corresponding to proteins of the electron transfer chain, rescuing mitochondrial function in cells with mutations or deletions in those genes.

Doris Taylor: Recellularized Human Hearts May be Weeks Away

Posted by Michael Rae on April 04, 2011 | Chief Science Officer's Team

Dr. Doris Taylor, the researcher whose team successfully engineered a live, beating rat heart via the technique of decellularisation and reseeding, has announced progress towards repeating the process with human tissue. Press reports based on Dr. Taylor's presentation at the American College of Cardiology's 60th Annual Scientific Session indicate that the hearts are growing well and are expected to begin beating within the next few weeks.

How (Not) to Run a Lifespan Study

Posted by Michael Rae on March 26, 2011 | Chief Science Officer's Team

Much of the distraction in the literature of biogerontology, and an even higher ratio of studies cited and promoted in the popular media and the dietary supplement industry, derives from methodologically-poor lifespan studies in mice (or occasionally rats). In these studies, an increase in mean or maximal lifespan is reported, relative to short-lived controls, and claimed to be informative about the universal, degenerative aging process and the prospects for extending healthy life in humans living in the developed world.

Research Report 2010

Posted by Aubrey de Grey, CSO on March 21, 2011 | Chief Science Officer's Team

I'm delighted to be able to share with you our research report, prepared for the first 10 months of 2010, by Tanya Jones (our Director of Research Operations), working with our researchers and my CSO Team.

Harnessing Wild Horses: New Roles of Free Radicals in Cell Signaling

Posted by Michael Rae on March 20, 2011 | Chief Science Officer's Team

The free radical theory of aging suggests that reactive oxygen species (ROS) and similar chemicals are responsible for a large part, or perhaps all, of the molecular and cellular damage that accumulates in aging bodies. However, more detailed analysis has revealed that some free radicals have essential signalling functions within the cell. These functions are likely to explain some of the failure of antioxidant therapy to extend lifespans in model organisms.

The Pathological Basis of "Normal" Cognitive Aging

Posted by Michael Rae on February 16, 2011 | Chief Science Officer's Team

Two recent publications clearly refute the principle arguments in favour of a distinction between "normal" cognitive aging, and pathological conditions such as Alzheimer's disease. Instead, it is increasingly apparent that the "normal" cognitive decline observed in all elderly and some middle-aged individuals is simply an earlier stage of the frank neuropathology observed in neurodegenerative disease. We emphasise that treating such conditions at this earlier, pre-clinical stage is likely to be more effective, as well as being more humane.

Clearing Out the Dead Wood: Rejuvenating Humoral Immunity through Ablation Strategy

Posted by Michael Rae on January 31, 2011 | Chief Science Officer's Team

The degenerative aging of the immune system is responsible for an enormous burden of disease and disability, from the pain of recurrent Herpes zoster and postherpetic neuralgia, to elevated rates of chronic urinary tract infections, to complications in wounds, pressure sores, ulcers, and surgical incisions. Most prominently, it underlies the meteoric rise in mortality from respiratory infections with age: influenza, pneumonia, and septicemia rise from being negligible causes of death in healthy middle-aged adults in the USA, to emerge amongst the top 10 causes of death in adults over the age of 55, with mortality rates climbing with each successive year of aging.

A CoDA for the Barriers to Genetic Rejuvenation Therapies?

Posted by Michael Rae on January 07, 2011 | Chief Science Officer's Team

Zinc finger nucleases (ZFNs) are engineered DNA-binding proteins with remarkable, highly programmable sequence-specificity. However, their widespread use has been slowed by licensing issues and the technical difficulty of synthesising new variants. A new platform, CoDA (context-dependent assembly), promises to make these exceptionally useful tools available to a far greater number of researchers.

Internal A2E synthesis capability created and protein purification improved

Posted by Tanya Jones, COO on January 02, 2011 | Degradation of A2E

One of our priorities at the SENS Foundation Research Center has been to overcome the limitations of our ability to test potential A2E-degrading enzymes caused by a restricted supply of the target molecule (A2E). We have now successfully synthesized A2E, purifying it by flash chromatography and HPLC, and confirming it to be identical to that produced in Janet Sparrow's laboratory through different analytical tests.

Toward Full Pluripotency of Reprogrammed Cells -- And Cautionary Tale About Abandoning the 'Gold Standard'

Posted by Michael Rae on December 09, 2010 | Chief Science Officer's Team

Induced pluripotent stem cells (iPSCs) are among the most exciting recent developments in biomedicine, overcoming immunological and ethical issues associated with the use of embryonic stem cells (ESCs). However, reasonable doubt remains regarding whether iPSCs do in fact have the full biological and therapeutic potential of ESCs. Work at the Harvard Stem Cell Institute recently produced the first "all-iPSC" live mice, a milestone on the road to establishing full equivalence between the two methods.

NIA's ITP Confirms: Resveratrol Does Not Extend Lifespan; Limited Benefit to Rapamycin

Posted by Michael Rae on October 27, 2010 | Chief Science Officer's Team

Resveratrol, a polyphenol famously found in wine, has previously been shown to extend lifespan in some naturally unhealthy rodent strains - but unfortunately does not show the same benefits in healthy, naturally long-lived mice. Meanwhile rapamycin, an immunosuppressant drug, has now become the first substance confirmed to at least moderately extend maximum lifespan in healthy mice.